Philips, Westchester decides to contract on precision medicine initiative

Ten-facility Westchester Medical Center Health Network in the region of Valhalla, N.Y., has inaugurated a precision medicine initiative to make better the cancer care enterprisewide across its acute and ambulatory facilities and services, and it has tapped Philips Healthcare as a primary supporting vendor.
The delivery system will utilize IntelliSpace Genomics product of Philips to combine and merge genomic sequencing information with clinical data, involving pathology, medical images, genomic databases and longitudinal patient records, and supported with health data exchange services to tailor treatment to genomic makeup of patient, and then establish therapy strategies at the point of care.
“Our precision medicine initiative for oncology is created to leverage entire available sources of critical information or data to help make the most informed decisions about each patient’s care,” claims John Fallon, MD, director of the department of clinical pathology at Westchester.
Westchester Medical Center has extra precision medicine initiatives in the works, like the new cellular and tissue engineering laboratory that supports and motivates cellular therapy under investigational latest drug applications covering hematological and oncological ailments.
The recently declared initiative follows the announcement previous year that Royal Philips and Westchester Medical Center had inaugurated a fifteen-year, $500 million partnership to transform and improve healthcare. The attempt is using an enterprise managed services model through which Philips gives the organization with a range of clinical and business consulting services, as well as advanced medical technologies. The partners claimed that they were seeking to “redefine how quality care is delivered.”